Public Market Listing
Live quotes, historical charts, and market capitalization for Sun Pharmaceutical Industries are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptor | Inflammatory Bowel Disease Crohn's Disease | |
Ferric pyrophosphate citrate(Triferic) | Approved | Iron-replacement therapy delivered via dialysateSmall molecule | Chronic Kidney DiseaseIron Deficiency Anemia |
| Approved | GABA-A receptorSmall molecule | Epilepsy | |
tildrakizumab(Ilumya) | Approved | IL-23 p19Monoclonal antibody | Psoriatic ArthritisPsoriasis |
Lerodalcibep(Lerochol) | Phase 3 | PCSK9Protein / enzyme therapeutic | Atherosclerotic Cardiovascular Disease |
| Phase 2 | GLP-1 receptorPeptide | ObesityType 2 Diabetes |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
April 2027 (1)
What to watch
2028 (2)
2031 (1)
July 2031 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (3)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | $1.5B | $91M | $1.2B | — | report ↗ |
Sun Pharmaceutical Industries reported revenue of $1,497.02M, down 74.4% YoY, R&D spend of $91.31M, down 75.8% YoY, and cash and equivalents of $1,201.86M for Q1 2025.
Figures only: this period's report disclosed no narrative text
View 2 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q4 | $1.6B | $98M | — | — | report ↗ |
| 2024-Q2 | $1.5B | $93M | — | — | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $6.6B | $401M | $1.0B | — | report ↗ |